UGT1A1

By Targets:	Autophagy (2) Cytochrome P450 (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (2) HBV (1) HIV (3) HIV Integrase (3) Keap1-Nrf2 (1) OAT (3) Prostaglandin Receptor (1) Small Interfering RNA (siRNA) (1) UGT (3)
By Research Areas:	Cancer (2) Endocrinology (3) Infection (4) Inflammation/Immunology (1) Metabolic Disease (5)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160250

UGT1A1-IN-1	UGT	Metabolic Disease
UGT1A1-IN-1 (compound 2) is a non-competitive inhibitor of *UGT1A1, which can inhibit the 1-O-glucuronidation process mediated by UGT1A1* with a K_i value of 5.02 μM. UGT1A1-IN-1 (compound 2) can bind on *UGT1A1* at the same ligand-binding site as bilirubin (HY-N0323). UGT1A1-IN-1 can serve as a ‘turn-on’ fluorescent probe substrate for UGT1A1 .

HY-111832

1,2,3,6-Tetragalloylglucose TeGG	UGT	Metabolic Disease
1,2,3,6-Tetragalloylglucose is a potent UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) inhibitor, with a K_i of 1.68 μM .

HY-N0372

Licochalcone A Maximum Cited Publications 11 Publications Verification Licochalcone-A	Autophagy	Cancer
Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and K_i values lower than 5 μM) .

HY-RS15426

UGT1A1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
UGT1A1 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

UGT1A1 Human Pre-designed siRNA Set A UGT1A1 Human Pre-designed siRNA Set A

HY-100319

UK-157147	UGT	Metabolic Disease
UK-157147 is a substrate for UDP-glucuronosyltransferases (UGT1A1) with a K_m value of 105 μM.

HY-124364

RO6889678	HBV Cytochrome P450	Infection Metabolic Disease
RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .

HY-135581

Raloxifene 6-glucuronide	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-N0372R

Licochalcone A (Standard)	Autophagy	Cancer
Licochalcone A (Standard) is the analytical standard of Licochalcone A. This product is intended for research and analytical applications. Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and Ki values lower than 5 μM) .

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium	Estrogen Receptor/ERR	Endocrinology
Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

HY-N1902R

4-Hydroxyphenylacetic acid (Standard)	Keap1-Nrf2 Endogenous Metabolite	Metabolic Disease
4-Hydroxyphenylacetic acid (Standard) is the analytical standard of 4-Hydroxyphenylacetic acid. This product is intended for research and analytical applications. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2 . IC₅₀ & Target:Nrf2 In Vivo: 4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1 .

HY-15592A

Cabotegravir sodium 5+ Cited Publications GSK-1265744 sodium; S/GSK1265744 sodium	OAT HIV HIV Integrase	Infection
Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS .

HY-15592

Cabotegravir 5+ Cited Publications GSK-1265744; S/GSK1265744	OAT HIV HIV Integrase	Infection
Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .

HY-15592R

Cabotegravir (Standard)	OAT HIV HIV Integrase	Infection
Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC₅₀ values of 2.5 nM, 0.41 μM and 0.81 μM for HIV_ADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .

HY-111539

BAY-1316957	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC₅₀ of 15.3 nM for human EP4-R. BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for endometriosis research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111832

1,2,3,6-Tetragalloylglucose TeGG	Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	UGT
1,2,3,6-Tetragalloylglucose is a potent UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) inhibitor, with a K_i of 1.68 μM .

HY-N0372

Licochalcone A 10+ Cited Publications Licochalcone-A	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Source classification Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Cancer	Autophagy
Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and K_i values lower than 5 μM) .

HY-N0372R

Licochalcone A (Standard)	Structural Classification Chalcones Flavonoids Leguminosae Source classification Plants Glycyrrhiza uralensis Fisch.	Autophagy
Licochalcone A (Standard) is the analytical standard of Licochalcone A. This product is intended for research and analytical applications. Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and Ki values lower than 5 μM) .

HY-N1902R

4-Hydroxyphenylacetic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Monophenols Source classification Phenols Plants Compositae Endogenous metabolite Erythrina latissima E. Mey.	Keap1-Nrf2 Endogenous Metabolite
4-Hydroxyphenylacetic acid (Standard) is the analytical standard of 4-Hydroxyphenylacetic acid. This product is intended for research and analytical applications. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2 . IC₅₀ & Target:Nrf2 In Vivo: 4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1 .

Cat. No.	Compare	Product Name	Species	Source

HY-P72277

	UGT1A1 Protein, Human (P.pastoris, His) BILIQTL1; UDP-glucuronosyltransferase 1-1	Human	P. pastoris
	The UGT1A1 protein is an important UDP-glucuronosyltransferase (UGT) that drives phase II biotransformation by conjugating lipophilic substrates with glucuronic acid, enhancing water solubility, and promoting excretion. UGT1A1 is critical for the elimination of drugs, xenobiotics, and endogenous compounds and exhibits multiple substrate specificities, glucuronidating estrogens, bilirubin, phytoestrogens such as genistein and daidzein, and SN -38. UGT1A1 Protein, Human (P.pastoris, His) is the recombinant human-derived UGT1A1 protein, expressed by P. pastoris , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium
Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

Raloxifene 6-glucuronide-d4 lithium

Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression[1][2][3].

Cat. No.	Product Name		Classification

HY-RS15426

UGT1A1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
UGT1A1 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides